iNtRON Biotechnology Inc Cash Flow-to-Debt Ratio
iNtRON Biotechnology Inc cash flow-to-debt ratio. iNtRON Biotechnology Inc (048530) has a Cash Flow-to-Debt Ratio of -0.21x as of September 2025, meaning its operating cash flow of ₩-993.53 Million could theoretically repay 0% of its total liabilities (₩4.73 Billion) in one year. Check iNtRON Biotechnology Inc cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of iNtRON Biotechnology Inc (2012–2024)
Cash flow-to-debt ratio of iNtRON Biotechnology Inc from 2012 to 2024. Historical debt coverage capacity for iNtRON Biotechnology Inc across 11 annual periods. Check 048530 capex plus investments ratio to assess the company's total reinvestment commitment from operating cash flow.
iNtRON Biotechnology Inc Cash Flow-to-Debt Ratio by Year (2012–2024)
iNtRON Biotechnology Inc cash flow-to-debt ratio by year from 2012 to 2024. Year-by-year debt coverage analysis for iNtRON Biotechnology Inc. For the full cash flow conversion analysis, see iNtRON Biotechnology Inc (048530) cash conversion ratio.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.05x | ₩-138.47 Million | ₩2.60 Billion | ▼ -103.2% |
| 2023 | 1.66x | ₩3.12 Billion | ₩1.88 Billion | ▲ +864.7% |
| 2022 | 0.17x | ₩5.98 Billion | ₩34.78 Billion | ▼ -45.7% |
| 2021 | 0.32x | ₩16.47 Billion | ₩52.02 Billion | ▼ -32.7% |
| 2020 | 0.47x | ₩7.13 Billion | ₩15.16 Billion | ▲ +1493.7% |
| 2019 | -0.03x | ₩-812.48 Million | ₩24.07 Billion | ▼ -112.6% |
| 2018 | 0.27x | ₩4.20 Billion | ₩15.70 Billion | ▲ +175.3% |
| 2017 | -0.36x | ₩-5.47 Billion | ₩15.38 Billion | ▲ +20.0% |
| 2016 | -0.44x | ₩-4.64 Billion | ₩10.46 Billion | ▼ -255.0% |
| 2015 | 0.29x | ₩1.70 Billion | ₩5.93 Billion | ▲ +768.1% |
| 2012 | -0.04x | ₩-331.01 Million | ₩7.72 Billion | — |